Comparative Effects of Individual Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials
Authors' conclusion
GLP-1RAs substantially improve body composition-related excess adiposity, but unfavourable effects on lean mass were observed, particularly at high doses.
Study context
- Population
- Adults with overweight or obesity, with or without T2D
- Participants
- 3,379 adults43 randomised controlled trials (RCTs)
- Comparison
- Individual GLP-1 RA-based medications vs control
- Outcome
- Change from baseline in body composition: total body fat (%), fat mass (kg), VAT area (cm²), SAT area (cm²), liver fat content (%), total lean tissue (%) and lean mass (kg)
Methodological detailsfrequentist network meta-analysis, random-effects model, CINeMA certainty appraisal
- Frequentist network meta-analysis
- Random-effects model
- CINeMA certainty appraisal
Pooled result
As reported in the abstract
Change in body composition from baseline (SMD)
SC liraglutide 1.8 mg/day, semaglutide 1.0 mg-weekly and tirzepatide 15 mg-weekly significantly decreased lean mass (standardised mean differences (SMDs) ranged)
−1.09 to −0.50
Original publication
Comparative Effects of Individual Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials. Diabetes Obes Metab. Published 28 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →